AACHEN, Germany and CAMBRIDGE, UK, Sept. 22, 2008 (GLOBE NEWSWIRE) -- The biopharmaceutical company PAION AG (ISIN DE000A0B65S3) (Frankfurt:PA8) (London AIM: PAI) today announces that its Phase I study with its sedative CNS 7056 has progressed to the dose levels that induce pronounced sedation. In addition, the first group including a comparison with midazolam, the current gold standard for procedural sedation has been completed. So far no safety concerns were raised by the Drug Safety Monitoring Board.
